–

On April 5, 2022, the U.S. Food and Drug Administration (FDA) revised the Emergency Use Authorization (EUA) to discontinue the administration of sotrovimab.

Bebtelovimab is Florida’s only available monoclonal antibody treatment.

–

On January 24, 2022, the U.S. Food and Drug Administration (FDA) revised the Emergency Use Authorizations (EUA) for Eli Lilly’s bamlanivimab-etesevimab and Regeneron’s REGEN-COV monoclonal antibody treatments, discontinuing their use by any U.S. state or jurisdiction. The full Florida Department of Health press release can be found here.